ArticleMolecular biology reports2026
Tankyrase inhibition restores chemosensitivity in triple-negative breast cancer cells by disrupting TFEB/β-Catenin/ABCG2 axis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy remains the most preferred therapeutic option for Triple-Negative breast cancer (TNBC), but patients frequently develop resistance over time, which remains a major clinical challenge, leading to poor patient treatment outcomes.
methodsWe established Cisplatin-resistant MDA-MB-231 cells. Cell viability and drug response were evaluated via the MTT and SRB assays. Colony formation and migration assays were conducted to assess clonogenic and metastatic capabilities. A comprehensive bioinformatics analysis was performed to identify differentially expressed genes. Protein expression and localisation analysis was conducted through western blotting and immunofluorescence. Functional validation was performed using siRNA-mediated knockdown, and protein interactions were evaluated by co-immunoprecipitation (Co-IP). In vivo studies assessed the therapeutic efficacy of TNKS inhibition with XAV-939 alone and in combination with cisplatin.
resultsThe study demonstrates that TFEB regulates the expression of the multidrug efflux transporter ATP-binding cassette subfamily G member 2 (ABCG2), a crucial factor in drug resistance mechanisms. The nuclear translocation of TFEB is demonstrated to rely on TNKS-mediated PARsylation, a post-translational modification that enhances its entry into the nucleus from the cytoplasm. Upon entering the nucleus, TFEB interacts with β-catenin to initiate the transcriptional activation of ABCG2. The pharmacological inhibition of TNKS via the utilisation of XAV-939 interferes with the trafficking of TFEB that is dependent on PARsylation, leading to a reduction in ABCG2 expression and thus compromised cisplatin efflux capability of CR cells.The in vivo studies validated the reduction in tumour growth following TNKS blockade, either alone or in conjunction with cisplatin.
conclusionTargeting TNKS represents a potentially effective therapeutic approach to address cisplatin resistance and improve treatment outcomes in TNBC.
Indexed as
Identifiers
42423804What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.